Glycaemic benefit of iGlarLixi in insulin‐naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan‐O randomized trial

In this post hoc analysis of the randomized controlled LixiLan‐O trial in insulin‐naive patients with type 2 diabetes mellitus (T2DM) not controlled with metformin, with or without a second oral antihyperglycaemic drug (OAD), the efficacy and safety of the fixed‐ratio combination, iGlarLixi (insulin...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Melanie J., Russell‐Jones, David, Barber, Thomas M., Lavalle‐González, Fernando J., Galstyan, Gagik R., Zhu, Dalong, Baxter, Mike, Dessapt‐Baradez, Cecile, McCrimmon, Rory J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772132/
https://www.ncbi.nlm.nih.gov/pubmed/31124299
http://dx.doi.org/10.1111/dom.13791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772132/
https://www.ncbi.nlm.nih.gov/pubmed/31124299
http://dx.doi.org/10.1111/dom.13791

Ejemplares similares